BAAR, Switzerland--(BUSINESS WIRE)--CorFlow Therapeutics AG (www.corflow-therapeutics.ch) today announced that the company has completed the 2nd close of its Seed+ financing round. To date, and since ...

BAAR, Switzerland, July 07, 2025--(BUSINESS WIRE)--CorFlow Therapeutics AG (CorFlow), a pioneering company in the field of cardiac care targeting microvascular disease, today announced that the U.S.

CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical ...

CorFlow Therapeutics has raised $48.5m (€44m) in a Series B financing round to advance its microvascular obstruction (MVO) detection device through a pivotal study ahead of market clearance, following ...

CorFlow Therapeutics is set to initiate a pivotal trial of its CorFlow CoFl system across US hospitals for patients being treated for heart attacks. This initiative comes after the receipt of the US ...

BAAR, Switzerland--(BUSINESS WIRE)--CorFlow Therapeutics AG ("CorFlow") announced today that Dr. Felice Gragnano, MD, Inselspital, Bern University Hospital, Bern, Switzerland, has presented interim ...

BAAR, Switzerland — CorFlow Therapeutics AG (CorFlow) is pleased to announce the appointment of Chris O’Connell as Chairman of the Board of Directors, replacing Rick Geoffrion who remains as a ...

The Series B funding enables both an International Pivotal trial to diagnose MVO and a randomized controlled trial to evaluate therapeutic treatments for MVO through ...

CorFlow Therapeutics AG (CorFlow) is pleased to announce the appointment of Chris O'Connell as Chairman of the Board of Directors, replacing Rick Geoffrion who remains as a Director on the Board.